Immutep eftilagimod alpha pembrolizumab TACTI-002 NSCLC 2024

Clinical presentation of TACTI-002 Phase II trial results combining eftilagimod alpha (soluble LAG-3), an antigen-presenting cell activator, with pembrolizumab for first-line metastatic non-small cell lung cancer. The study evaluated 114 patients and demonstrated the rationale for combining efti's APC activation with PD-1 antagonists to enhance immune responses and disease control.